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Abstract:  Cyanidin  and  its  glycosides  are  naturally  dietary  pigments  which  have  been 
indicated as promising candidates to have potential benefits to humans, especially in the 
prevention  and  treatment  of  diabetes  mellitus.  We  investigated  the  structure  activity 
relationships  of  cyanidin  and  its  glycosides  to  inhibit  intestinal  -glucosidases  and 
pancreatic -amylase in vitro. The results found that cyanidin and its glycosides are more 
specific inhibitors of intestinal sucrase than intestinal maltase. Cyanidin-3-galactoside and 
cyanidin-3-glucoside  were  the  most  potent  inhibitors  against  intestinal  sucrase  and 
pancreatic -amylase with IC50 values of 0.50  0.05 and 0.30  0.01 mM, respectively. 
Our findings indicate that the structural difference between glucose and galactose at the  
3-O-position of cyanidin was an important factor for modulating the inhibition of intestinal 
sucrase and pancreatic -amylase. The combination of cyandin-3-glucoside, cyanidin-3-
galactoside  or  cyanidin-3,5-diglucosides  with  a  low  concentration  of  acarbose  showed 
synergistic inhibition on intestinal maltase and sucrase. The synergistic inhibition was also 
found for a combination of cyanidin or cyanidin-3-glucoside with a low concentration of 
acarbose. The findings could provide a new insight into a use for the naturally occurring 
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intestinal  -glucosidase  and  pancreatic  -amylase  inhibitors  for  the  prevention  and 
treatment of diabetes and its complications. 
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1. Introduction 
Anthocyanins are the largest group of water-soluble pigments in the Plant Kingdom. They have 
been  recently  demonstrated  to  have  potential  health
 benefits  and  disease  prevention  properties  in 
animals and humans. Anthocyanins are included in the list of natural compounds known as potential 
antioxidants  [1].  Consumption  of  anthocyanin-enriched  foods  is  associated  with  a  reduced  risk of 
several diseases such as atherosclerosis [2] dyslipidemia [3], and diabetes [4]. The delaying digestion 
of disaccharides to absorbable monosaccharides by inhibition of -amylase and -glucosidase is one 
therapeutic approach for controlling postprandial hyperglycemia in pre-diabetes and diabetes [5]. The 
suppression of postprandial hyperglycemia subsequently delays the progression of micro- and macro-
vascular complications such as microangiopathy, cardiovascular, and cerebrovascular diseases [6].  
Cyanidin and its glycosides (Figure 1) belong to anthocyanins, and are widely distributed in various 
human diets through crops, vegetables, fruits, and red wine suggesting that we daily ingest significant 
amounts  of these compounds from  plant-based diets  [7].  Interestingly, cyanidin and its  glycosides 
represent one of the major groups of naturally occurring anthocyanins; their mechanisms related to 
anti-diabetic  effects  have  been  deeply  investigated  [4].  Recent  studies  suggesting  that  cyanidin-3-
galactoside potentially inhibits mammalian intestinal -glucosidases have renewed interest in studies 
on delaying postprandial hyperglycemia and hyperinsulinemia. The kinetic model proposed for this 
type of inhibition shows that cyanidin-3-galactoside is a mixed type pattern against intestinal sucrase 
[8].  The  combination  of  acarbose  and  cyanidin-3-galactoside  has  a  synergistic  effect  on  intestinal  
-glucosidase inhibition [8]. Our previous study indicates that cyanidin-3-rutinoside also exhibits an 
inhibitory  effect  on  yeast  -glucosidase  in  a  non-competitive  manner  [9].  Although  the 
-glucosidase inhibitory activities of cyanidins are well-documented, studies regarding the structure-
activity relationship of cyanidin and its glycosides on the inhibition of -glucosidases and pancreatic 
-amylase have not been undertaken. Therefore, the aim of this study was to investigate the structure 
relationship of cyanidin and its glycosides on inhibition of mammalian -glucosidases and pancreatic 
-amylase. Furthermore, the combined effect of acarbose by these compounds was also investigated. 
The results of our investigation provide useful information for the development of natural compounds 
in order to prevent and treat diabetes mellitus. 
2. Material and Methods 
2.1. Chemicals 
Rat  intestinal  acetone  powder,  porcine  pancreatic  -amylase,  3,5-dinitrosalicylic  acid,  glucose 
oxidase kits were purchased from Sigma Chemical Co. Ltd. (St. Louis, MO). Acarbose was obtained Int. J. Mol. Sci. 2010, 11                       
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from  Bayer,  Germany.  Cyanidin  chloride,  cyanidin-3-glucoside  chloride,  cyanidin-3-galactoside 
chloride, and cyanidin-3,5-diglucoside were purchased from Chromadex, USA. All others chemicals 
used were of analytical grade. 
Figure 1. The structure of cyanidin and its glycosides. 
 
2.2.-Glucosidase Inhibition Assay 
The assessment of -glucosidase inhibitory activity was performed according to our previous report 
[10].  Briefly,  100  mg  of  rat  intestinal  acetone  powder  was  homogenized  in  3  mL  of  0.9%  NaCl 
solution. After centrifugation (12,000 g ×  30 min), 10 L of the supernatant (maltase = 0.68 units/mg 
protein, sucrase = 0.10 units/mg protein) was incubated with 70 L of substrate solution (37 mM 
maltose, 54 mM sucrose), and 20 L of sample at various concentrations in 0.1 M phosphate buffer  
pH 6.9 at 37 ° C for 30 min (maltase assay) and 60 min (sucrase assay). The mixtures were suspended 
in boiling water for 10 min to stop the reaction. The concentrations of glucose released from the 
reaction mixtures were determined by glucose oxidase method. Acarbose was used as a positive control 
for this assay. 
2.3. Pancreatic -Amylase Inhibition Assay 
The pancreatic -amylase inhibition assay was performed according to our previous reports [10]. 
Porcine pancreatic -amylase was dissolved in 0.1 M phosphate buffer saline, pH 6.9. The various 
concentrations of test compounds were added to solution containing in 1 g/L starch and phosphate Int. J. Mol. Sci. 2010, 11                       
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buffer. The reaction was initiated by adding amylase (3 U/mL) to the incubation medium to a final 
volume of 500 µL. After 10 min, the reaction was stopped by adding 0.5 mL dinitrosalicylic (DNS) 
reagent (1% 3,5-dinitrosalicylic acid, 0.2% phenol, 0.05% Na2SO3, and 1% NaOH in aqueous solution) 
to the reaction mixture. The mixtures were heated at 100 ° C for 10 min and 500 µL of 40% potassium 
sodium  tartarate  solution  was  added  to  the  mixtures  to  stabilize  the  color.  After cooling to  room 
temperature  in  a  cold  water  bath,  absorbance  was  recorded  at  540 nm  using  a  spectrophotometer. 
Acarbose was used as a positive control for this assay 
2.4. Combined Effect of Acarbose by Cyanidin and Its Glycosides 
The various concentrations of acarbose were combined with or without cyanidin and its glycosides 
at low concentration. The reaction was performed according to the above assay (-glucosidase and 
pancreatic  -amylase).  Results  were  expressed  as  a  percentage  inhibition  of  the  corresponding  
control values. 
2.5. Statistical Analysis  
Data  were  expressed  as  means ±  S.E.M.  The  IC50  values  were  calculated  from  plots  of  log 
concentration of inhibitor concentration versus percentage inhibition curves by using Sigma Plot 10.0 
(IL, USA). Statistical analysis was performed by Student’s t test. 
3. Results  
As shown in Table 1, cyanidin and its glycosides moderately inhibited intestinal sucrase but were 
not active against intestinal maltase. The IC50 value of cyanidin was 1.42  0.25 mM against intestinal 
sucrase. Upon the introduction of 3-O-glucose moiety of cyanidin, it was found that the IC50 value of 
cyanidin-3-glucoside decreased intestinal sucrase inhibition by 1.46-fold as compared with cyanidin. 
Furthermore,  the  addition  of  5-O-glucose  moiety  in  cyanidin-3-glucoside  gave  cyandin-3,5-
diglucoside, which is an inactive intestinal sucrase inhibitor. Meanwhile, replacement of a residue at  
3-O-glucose  of  cyanidin  by  a  3-O-galactose  moiety  resulted  in  a  significant  increase  in  intestinal 
sucrase inhibitory activity. It was observed that intestinal sucrase inhibitory activities increased in the 
order  of  cyanidin-3-galactoside  >  cyanidin-3-glucoside  >  cyanidin  >  cyanidin-3,5-diglucoside. 
However, cyanidin and its glycosides were less potent than that of acarbose on the intestinal maltase 
and sucrase inhibition.  
Table 1 shows the ability of each compound to inhibit pancreatic -amylase. The IC50 value of 
cyanidin-3-glucoside  was  a  better  pancreatic  -amylase  inhibitor  than  the  other  three  kinds  of 
cyanidins. Meanwhile, cyanidin-3-galactoside and cyanidin-3,5-diglucoside had no inhibitory activity 
against pancreatic -amylase. It should be noted that acarbose with pancreatic -amylase inhibitory 
activity, which was used as a positive control, showed an IC50 of 0.12 ±  0.04 mM in our assay system.  Int. J. Mol. Sci. 2010, 11                       
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Table 1. The IC50 values for intestinal -glucosidase (maltase and sucrase) and pancreatic 
-amylase by cyanidin and its glucosides. 
Compounds  IC50 values (mM)  
   Maltase  Sucrase  -Amylase 
Cyanidin   >3.00  1.42 ±  0.25  0.38 ±  0.01 
Cyanidin-3-glucoside   >3.00  0.97  0.05  0.30 ±  0.01 
Cyanidin-3-galactoside  >3.00  0.50 ±  0.05
a  >1.00 
Cyanidin-3,5-diglucoside  
Acarbose 
>3.00 
0.003 ±  0.001 
>2.00 
0.09 ±  0.04 
>1.00 
0.12 ±  0.04 
Results were expressed as means ±  S.E.M., n = 3.  
aThe IC50 value of cyanidin-3-galactoside was previously reported in Adisakwattana et al. [8].  
It  was  of  interest  to  establish  whether  cyanidin  and  its  glycosides  and  acarbose  might  interact 
synergistically on intestinal -glucosidase and pancreatic -amylase. Therefore, the assay was then 
performed in  solutions  containing acarbose alone or in mixture with  a low concentration of these 
compounds (1 M). The combined effects of acarbose together with cyanidin and its glycosides on 
intestinal maltase inhibition are shown in Figure 2.  
The results showed that cyanidin and its glycosides (1 M) had no inhibitory activity on intestinal 
maltase  and  sucrase  (data  not  shown).  When  cyanidin-3-galactoside,  cyanidin-3-glucoside,  and 
cyanidin-3,5-diglucoside  was  added  to  the  assay  system  with  acarbose  (0.05  µM),  the  percentage 
intestinal maltase inhibition was increased when compared with acarbose alone. When each compound 
was added to the assay system containing a low concentration of acarbose (3.12 µM), the percentage 
intestinal sucrase inhibition markedly increased (Figure 3). No change in the percentage of intestinal 
maltase and sucrase inhibition was observed in the presence of the combination of low concentration of 
cyanidin and acarbose. The findings indicate that cyanidin-3-galactoside, cyanidin-3-glucoside, and 
cyanidin-3,5-diglucoside produce synergistic effects on intestinal maltase and sucrase inhibition when 
combined with a low concentration of acarbose.  
The  results  showed  that  cyanidin  and  its  glycosides  (1.0  M)  had  no  inhibitory  activity  on 
pancreatic -amylase inhibition (data not shown). When adding each compound (1.0 μM) to acarbose 
(3.12 μM), cyanidin or cyanidin-3-glucose significantly increased the percentage pancreatic -amylase 
inhibition  (Figure  4),  whereas  cyanidin-3-galactoside  and  cyanidin-3,5-diglucoside  did  not  show 
significant changes in the percentage inhibition when compared acarbose alone. Our findings suggest 
that cyanidin and cyanidin-3-glucoside produce synergistic effect on pancreatic -amylase inhibition 
when combined with a low concentration of acarbose.  
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Figure 2. The combined effect of acabose and cyanidins on intestinal maltase inhibition.  
(1): 0.05 µM acarbose; (2): 0.05 µM acarbose + 1 M cyanidin; (3): 0.05 M acarbose + 1 µM 
cyanidin-3-glucoside;  (4):  0.05  M  acarbose  +  1  µM  cyanidin-3-galactoside;  
(5):  0.05  µM  acarbose  +  1  M  cyanidin-3,5-diglucoside.  Result  are  expressed  as  
means  S.E.M; n = 3. *P < 0.001 compared with acarbose (0.05 µM) alone. 
 
Figure  3.  The combined effect of acabose and cyanidins on intestinal sucrase inhibition.  
(1): 3.12 M acarbose; (2): 3.12 M acarbose + 1 M cyanidin; (3): 3.12 M acarbose + 1 M 
cyanidin-3-glucoside;  (4):  3.12  M  acarbose  +  1  M  cyanidin-3-galactoside;  
(5):  3.12  M  acarbose  +  1  M  cyanidin-3,5-diglucoside.  Result  are  expressed  as  
means  S.E.M; n = 3. *P < 0.001 compared with acarbose (3.12 M) alone. 
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Figure  4.  The  combined  effect  of  acabose  and  cyanidins  on  pancreatic  -amylase 
inhibition.  (1):  3.12  M  acarbose;  (2):  3.12  M  acarbose  +  1  M  cyanidin;  
(3):  3.12  M  acarbose  +  1  M  cyanidin-3-glucoside;  (4):  3.12  M  acarbose  +  1  M 
cyanidin-3-galactoside; (5): 3.12 M acarbose + 1 M cyanidin-3,5-diglucoside. Result are 
expressed as means  S.E.M; n= 3. *P < 0.001 compared with acarbose (3.12 M) alone. 
 
4. Discussion  
This is the first study to investigate the structure-activity relationships of cyanidin and its glycosides 
on intestinal -glucosidase (maltase and sucrase) and pancreatic -amylase inhibition. According to 
our  results,  inhibition  of  intestinal  sucrase  by  cyanidin  and  its  glycosides  is  more  specific  than 
inhibition of intestinal maltase. In addition, cyanidin is a weak pancreatic -amylase and intestinal 
sucrase inhibitor, whereas cyanidin-3-glucoside is a more potent inhibitor than cyanidin. These results 
indicate  that  the  presence  of  3-O-glucoside  is  important  for  inducing  potent  inhibition  against 
pancreatic -amylase and intestinal sucrase. Increasing bulkiness at the 5-O-position by the glucose 
moiety  of  cyanidin-3-glucoside  dramatically  decreased  the  potency  of  pancreatic  -amylase  and 
intestinal  sucrase  inhibition,  suggesting  that  this  certain  position  may  not  necessarily  require  the 
presence of a glucose residue. This position may serve as the region for binding to the active site of 
pancreatic -amylase and intestinal sucrase.  
One  interesting  finding  is  that  the  replacement  of  3-O-glucose  of  cyanidin-3-glucoside  by  a 
galactose  residue  directly  increases  intestinal  sucrase  inhibitory  activity,  whereas  it  dramatically 
decreases  pancreatic  -amylase  inhibitory  activity.  When  comparing  the  structure  of  glucose  and 
galactose,  the  molecules  have  the  same  molecular  formula  but  different  structural  formulae.  The 
position of the hydroxyl (-OH) group on C-4 is the only distinction between glucose and galactose 
(Figure  1).  We  suggest  that  the  structural  difference  of  the  sugar  at  the  3-O-position  may  be  an 
important factor for modulating the inhibition of intestinal sucrase and pancreatic -amylase. A recent 
study has shown that the inhibitory activity of flavonols and flavones depends on hydrogen bonds 
between the hydroxyl groups of the polyphenol ligands and the catalytic residues of the binding site Int. J. Mol. Sci. 2010, 11                       
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and formation of a conjugated pi-system that stabilizes the interaction with the active site [11]. The 
molecular interaction of cyanidin and its glycosides on specific binding site on intestinal -glucosidase 
and pancreatic -amylase remains unclear. From the information of flavonols and flavones mentioned 
above, it can be assumed that cyanidin and its glycosides may interact with protein by using hydroxyl 
groups in their molecular structure, resulting in the formation of hydrogen bonds with the polar groups 
(amide, guanidine, peptide, amino and carboxyl groups) in the active site of proteins by covalent and/or 
non-covalent interactions. To prove this hypothesis, X-ray crystallography and computer modeling to 
evaluate the binding activity of cyandin and its glycosides on intestinal -glucosidase and pancreatic  
-amylase is needed to further investigation. 
Cyanidin-3-glucoside is a typical anthocyanin that is most abundant in black rice and purple corn 
[12,13]. It has been shown that dietary cyanidin-3-glucoside-riched purple corn significantly reduces 
blood glucose concentration and enhances insulin sensitivity in type 2 diabetic mice by upregulating 
the glucose transporter 4 (Glut4) and downregulating retinol binding protein 4 (RBP4) in the white 
adipose tissue [14]. In addition, cyanidin-3-glucoside also demonstrates a protective action against 
H2O2- or TNF-α-induced insulin resistance in 3T3-L1 adipocytes by inhibiting the c-Jun NH2-terminal 
kinase  (JNK)  signal  pathway  [15].  Recent  studies  have  shown  that  cyanidin-3-glucoside  and  
cyanidin-3-galactoside  directly  stimulate  insulin  secretion  from  a  pancreatic-cell  line  [16]. 
Considering the data obtained from our investigations, it is especially noteworthy that cyanidin and its 
glycosides  play  another  role  in  controlling  of  postprandial  hyperglycemia  by  inhibiting  intestinal  
-glucosidase and pancreatic -amylase. This inhibitory action may contribute to decreasing the level 
of HbA1c, resulting in a significant reduction in the incidence of chronic vascular complication in 
diabetic patients [17].  
Acarbose, -glucosidase inhibitor, has been clinically studied in type 2 diabetes mellitus. A recent 
report has shown that acarbose treatment was associated with a 25% reduction in the incidence of 
diabetes [18]. Treatment of acarbose leads to a 20% reduction
 of the postprandial peak of glycemia. 
This effect may last
 for as much as 5 h, with an increase in the time of glucose
 absorption that prevents 
glucotoxicity and the consequent
 hyperinsulinemia [19]. The lowest dose of acarbose with clinical 
effects  is  150  mg/day,
  with  doses  >300  mg/day  already  exceeding  the  saturated  binding  of  
-glucosidase, and causing no increase in the inhibitory effect
 of this drug [20,21].
 The most common 
adverse effect of acarbose is gastrointestinal disturbance
 such as flatulence, meteorism and abdominal 
distention which occurs in a dose
-dependent manner [19]. Anthocyanins occur frequently in food items 
such as berries, vegetables, cereals, and red wines. The average of daily intake of anthocyanins in 
human has been estimated to be 180−215 mg [22]. Thus, it is possible that intake of cyanidin and 
glycosides-enriched plant foods together with acarbose may lead to the development a novel combined 
therapy in type 2 diabetic patients. Our present study shows that combination with a low concentration 
of acarbose and some cyanidins produces more synergistic inhibition than either drug alone, suggesting 
that  they  may  provide  a  significant  clinical  benefit  in  delaying  postprandial  hyperglycemia.  As  a 
consequence of these synergistic effects, it is possible to reduce dosage of acarbose by combination 
with  cyanidin  and  its  glycosides,  resulting in  a  diminished adverse effect  of acarbose. The  intake 
amount of cyanidin and its glycosides that is required together with low dose of acarbose also needs 
further investigation in diabetic patients. Int. J. Mol. Sci. 2010, 11                       
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5. Conclusion 
Although  cyanidin  and  its  glycosides  have  been  investigated  for  possible  mechanisms  of  
anti-diabetic  activities,  the  present  study  shows  that  these  compounds  markedly  inhibit  intestinal  
-glucosidase and pancreatic -amylase, which is one of the therapeutic approaches for treatment of 
diabetes mellitus.  This  is  the first  report of  the combined effect  of acarbose and cyanidin and its 
glucosides.  Improvement  in  postprandial  hyperglycemia,  hyperinsulinemia  and  insulin  resistance, 
treatment of an overweight condition and diminishing of the adverse effects of acarbose in diabetic 
control can be clinically achieved by this combination. 
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